Takahashi T, Tsujino D, Kato Y, Wada Y, Someya K, Itagaki K, Imanishi Y, Ishikawa T, Sakaki T, Sasaki Y
3rd Dept. of Int. Med., St. Marianna Univ. School of Med.
Gan No Rinsho. 1989 Jun;35(7):828-33.
The clinical usefulness of a I-131 anti CEA F(ab')2 MoAB and CA 19-9 F(ab')2 MoAB cocktail(IMACIS-1) for the localization of a cancer has been studied in 35 patients (Lung Ca. 10, Pancreas Ca. 7, Gastric Ca. 6, Colon Ca. 5, Hepatoma 2, Cholangio Ca. 2, Esophageal Ca. 1, Uterus Ca. 1, and, Retroperitoneal tumor 1). Of these 28 patients (80%) had an abnormal accumulation of radioactivity in the tumor sites (Lung Ca. 5, Pancreas Ca. 7, Gastric Ca. 6, Colon Ca. 5, Hepatoma 2, Esophageal Ca. 1, Uterus Ca. 1, and, Retroperitoneal tumor 1). Eighteen cases (56.3%) in 32 cases in which the primary site was known showed an abnormal radioactive accumulation and, similarly, 20 metastatic sites (71.4%) in 16 cases with 28 metastatic sites also showed an abnormal accumulation of radioimmunoscintigraphy showed no correlation with the serum CEA or CA 19-9 concentration. Further, no side effect was observed.
已对35例患者（肺癌10例、胰腺癌7例、胃癌6例、结肠癌5例、肝癌2例、胆管癌2例、食管癌1例、子宫癌1例、腹膜后肿瘤1例）研究了I-131抗癌胚抗原F(ab')2单克隆抗体和CA 19-9 F(ab')2单克隆抗体混合物（IMACIS-1）用于癌症定位的临床实用性。其中28例患者（80%）肿瘤部位有放射性异常聚集（肺癌5例、胰腺癌7例、胃癌6例、结肠癌5例、肝癌2例、食管癌1例、子宫癌1例、腹膜后肿瘤1例）。在已知原发部位的32例患者中，18例（56.3%）有放射性异常聚集，同样，在有28个转移部位的16例患者中，20个转移部位（71.4%）也有放射性异常聚集。放射免疫闪烁显像与血清癌胚抗原或CA 19-9浓度无相关性。此外，未观察到副作用。
